New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
10:01 EDTHLT, OMED, SNAK, VSTM, TMO, MTD, T, AHPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at Drexel Hamilton... Ashford Hospitality Prime (AHP) initiated with a Buy at SunTrust... Cypress Energy (CELP) initiated with an Outperform at Raymond James... Hilton Worldwide (HLT) initiated with a Positive at Susquehanna... OncoMed (OMED) initiated with a Buy at Mizuho... RSP Permian (RSPP) initiated with an Overweight at Barclays... The Inventure Group (SNAK) initiated with an Outperform at Wedbush... Verastem (VSTM) initiated with a Buy at Mizuho... Xilinx (XLNX) initiated with a Buy at MKM Partners... RSP Permian (RSPP) initiated with an Outperform at Raymond James... Thermo Fisher (TMO) resumed with an Overweight at JPMorgan... Mettler-Toledo (MTD) initiated with a Market Perform at Wells Fargo.
News For T;AHP;HLT;OMED;SNAK;VSTM;TMO;MTD From The Last 14 Days
Check below for free stories on T;AHP;HLT;OMED;SNAK;VSTM;TMO;MTD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 16, 2014
14:03 EDTTNetflix submits FCC comments on proposed Net Neutrality rules
Subscribe for More Information
13:05 EDTTVerizon, Comcast, AT&T viwed as 'logical' Time Warner bidders, Bloomberg says
Subscribe for More Information
12:42 EDTTTime Warner said to see Verizon,Comcast, AT&T as logical bidders, Bloomberg says
Subscribe for More Information
11:28 EDTTMOLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
08:32 EDTOMEDOncoMed initiates Phase 2 ALPINE trial of tarextumab
OncoMed Pharmaceuticals announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's "ALPINE", or Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety, clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab, being studied for the treatment of pancreatic cancer. Tarextumab is being tested in combination with Abraxane plus gemcitabine in patients with previously untreated stage IV pancreatic cancer. The ALPINE trial is being conducted at up to 30 sites in the U.S. and is expected to enroll approximately 124 patients. The Phase 2 clinical trial will compare the progression-free survival, or PFS, of 15 mg/kg tarextumab administered every two weeks versus placebo in combination with Abraxane plus gemcitabine in all patients. Additionally, PFS will be assessed using a predictive biomarker for high tumor Notch3 expression. Secondary and exploratory endpoints, including overall survival and overall response rate, pharmacokinetics, safety and other biomarkers, will also be evaluated.
07:43 EDTTSenate Commerce, Science & Transportation Committee holds a hearing
Subscribe for More Information
July 15, 2014
08:03 EDTTPublic speak out on FCC 'net-neutrality' plan, WSJ says
The Federal Communications Commission's has received more than 677K comments so far from the public on its proposed 'net-neutrality' rules for how broadband providers can treat content traveling over their networks and a random sampling of the input suggests that the agency will have work to do to sell the plan, according to The Wall Street Journal. Companies that provide broadband Internet service include Comcast (CMCSA), AT&T (T), Verizon (VZ) Time Warner Cable (TWC), and Cablevision (CVC). Netflix (NFLX) sends a great deal of content over the Internet and strongly supports net neutrality. Reference Link
07:15 EDTTIIR Holdings to hold a conference
14th Annual Shopper Insights in Action Conference to be held in Chicago on July 14-16.
July 14, 2014
11:17 EDTTDemand Media announces divestiture of Creativebug and CoveritLive
Subscribe for More Information
10:34 EDTTAT&T joint venture acquires Creativebug from Demand Media for $10M
Otter Media, a joint venture between AT&T (T) and The Chernin Group, has acquired Creativebug from Demand Media (DMD), the companies announced earlier. Creativebug offers do-it-yourself video workshops featuring instruction from artists and designers. Demand Media confirmed in a regulatory filing earlier that it completed the sale of substantially all of the assets relating to its Creativebug business for $10.0M in cash. AT&T and The Chernin Group announced the formation of the joint venture to acquire, invest in and launch over-the-top video services previously on April 22.
09:31 EDTTAT&T, EPIX reach carriage agreement
Subscribe for More Information
08:32 EDTTSynchronoss acquires Voxmobili for $26M in cash
Synchronoss (SNCR) announced its acquisition of Voxmobili, a wholly owned subsidiary of OnMobile Global. Voxmobili’s customers include AT&T (T), Airtel, Everything Everywhere, France Telecom, Orange (ORAN), T-Mobile (TMUS), and Vodafone (VOD). In consideration for the acquisition, Synchronoss paid approximately $26M in cash to OnMobile Global.
July 10, 2014
16:09 EDTVSTMVerastem says lead cancer stem cell inhibitor VS-6063 continues to show promise
Verastem hosted its annual Research and Development Day, at which it reports it said, "We continue to see promising clinical signals from the VS-6063 program. An additional partial response has been reported since our interim report at ASCO on the combination of VS-6063 and weekly paclitaxel in twenty-two patients with ovarian cancer. To date, best clinical response of at least stable disease has been observed in 14 of the 22 patients. This comprises two complete responses, three partial responses and nine patients with stable disease, including four patients whose disease has been stable for 6 months or longer. Eight patients continue on study drug. Based on this encouraging activity, we are planning a controlled Phase 2 study in patients with platinum resistant ovarian cancer.” The company also noted that it has made "significant progress in the past 12 months and have continued to further scientific understanding with all of our product candidates." Encouraged by these initial signs of clinical activity, the company reported it is adding additional studies to further test its hypothesis that the targeting of cancer stem cells may enable a more durable clinical response.
July 9, 2014
15:54 EDTTDISH expresses concerns over Comcast, AT&T deals to FCC
Subscribe for More Information
09:32 EDTHLTSabre renews technology agreement with Hilton
Subscribe for More Information
09:23 EDTTAT&T exec sees connectivity, healthcare at forefront of wearables, Re/code says
Glenn Lurie, who heads AT&T’s (T) emerging-business efforts, said at the MobileBeat conference that he sees wearables devices needing their own Internet connectivity to take off and that he believes healthcare-focused devices, especially those serving the aging population, as a logical starting place for such devices, according to Re/code. Lurie also predicted that wearables will explode, “just like tablets," when a device maker cracks the code to making them easier to use. Reference Link
08:15 EDTSNAKInventure Foods weakness a buying opportunity, says Canaccord
Canaccord said weakness in Inventure Foods caused by the filing of a shelf registration In June has created a buying opportunity. The firm cited valuation, expectations for solid Q2 results, and an increase in its frozen capacity. Canaccord has a Buy rating with a $15.50 price target on the stock.
July 8, 2014
10:28 EDTVSTMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:00 EDTTSprint tests discounted versions of Framily, individual plans, CNet reports
Subscribe for More Information
06:59 EDTTMobile payments company Isis to change name
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use